Copy to clipboard 
Amplitude Surgical reported FY 4Q21 orthopedic revenue of $26.8 million, +85.8% vs. FY 4Q20 with full-year FY20 revenue of $116.5 million, +8.2% vs. FY20. COVID’s sharpest impact hit the company at the end of its last fiscal year, but successive waves of the pandemic dogged Amplitude throughout this fiscal year, as well.
Even before the COVID-era, Amplitude’s momentum slowed (+2.2% in FY19) relative to the market average growth rates for the segments where the company plays. However, its NOVASTEP foot and ankle line is a notable bright spot as it continues to gain traction in the U.S. For FY21, Novastep accounted for just over 13% of Amplitude’s total revenue.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $21.5 | $12.2 | $9.3 | 76.5% |
| Knees | $12.3 | $7.0 | $5.4 | 77.3% |
| Hips | $9.1 | $5.2 | $3.9 | 75.4% |
| Trauma | $4.0 | $1.6 | $2.4 | 153.8% |
| Sports Medicine | $0.8 | $0.4 | $0.3 | 79.4% |
| Orthobiologics | $0.6 | $0.3 | $0.3 | 114.5% |
| Total | $26.8 | $14.4 | $12.4 | 85.8% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $95.6 | $91.7 | $3.9 | 4.2% |
| Knees | $55.3 | $53.7 | $1.6 | 3% |
| Hips | $40.3 | $38.0 | $2.3 | 6% |
| Trauma | $15.6 | $10.6 | $5.0 | 47.1% |
| Sports Medicine | $3.2 | $3.2 | ($0.0) | (1.3%) |
| Orthobiologics | $2.1 | $2.1 | ($0.0) | (1.3%) |
| Total | $116.5 | $107.7 | $8.8 | 8.2% |
Geographic Sales
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $17.1 | $8.7 | $8.4 | 97.2% |
| International | $9.7 | $5.8 | $4.0 | 68.7% |
| Subsidiaries | $7.3 | $4.5 | $2.8 | 62.6% |
| Distributors | $2.5 | $1.3 | $1.2 | 89.8% |
| Total | $26.8 | $14.4 | $12.4 | 85.8% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $76.1 | $67.4 | $8.7 | 13% |
| International | $40.4 | $40.3 | $0.1 | 0.2% |
| Subsidiaries | $30.7 | $29.6 | $1.1 | 3.7% |
| Distributors | $9.7 | $10.7 | ($1.0) | (9.7%) |
| Total | $116.5 | $107.7 | $8.8 | 8.2% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Amplitude Surgical reported FY 4Q21 orthopedic revenue of $26.8 million, +85.8% vs. FY 4Q20 with full-year FY20 revenue of $116.5 million, +8.2% vs. FY20. COVID's sharpest impact hit the company at the end of its last fiscal year, but successive waves of the pandemic dogged Amplitude throughout this fiscal year, as well.
Even before the...
Amplitude Surgical reported FY 4Q21 orthopedic revenue of $26.8 million, +85.8% vs. FY 4Q20 with full-year FY20 revenue of $116.5 million, +8.2% vs. FY20. COVID’s sharpest impact hit the company at the end of its last fiscal year, but successive waves of the pandemic dogged Amplitude throughout this fiscal year, as well.
Even before the COVID-era, Amplitude’s momentum slowed (+2.2% in FY19) relative to the market average growth rates for the segments where the company plays. However, its NOVASTEP foot and ankle line is a notable bright spot as it continues to gain traction in the U.S. For FY21, Novastep accounted for just over 13% of Amplitude’s total revenue.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $21.5 | $12.2 | $9.3 | 76.5% |
| Knees | $12.3 | $7.0 | $5.4 | 77.3% |
| Hips | $9.1 | $5.2 | $3.9 | 75.4% |
| Trauma | $4.0 | $1.6 | $2.4 | 153.8% |
| Sports Medicine | $0.8 | $0.4 | $0.3 | 79.4% |
| Orthobiologics | $0.6 | $0.3 | $0.3 | 114.5% |
| Total | $26.8 | $14.4 | $12.4 | 85.8% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $95.6 | $91.7 | $3.9 | 4.2% |
| Knees | $55.3 | $53.7 | $1.6 | 3% |
| Hips | $40.3 | $38.0 | $2.3 | 6% |
| Trauma | $15.6 | $10.6 | $5.0 | 47.1% |
| Sports Medicine | $3.2 | $3.2 | ($0.0) | (1.3%) |
| Orthobiologics | $2.1 | $2.1 | ($0.0) | (1.3%) |
| Total | $116.5 | $107.7 | $8.8 | 8.2% |
Geographic Sales
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $17.1 | $8.7 | $8.4 | 97.2% |
| International | $9.7 | $5.8 | $4.0 | 68.7% |
| Subsidiaries | $7.3 | $4.5 | $2.8 | 62.6% |
| Distributors | $2.5 | $1.3 | $1.2 | 89.8% |
| Total | $26.8 | $14.4 | $12.4 | 85.8% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $76.1 | $67.4 | $8.7 | 13% |
| International | $40.4 | $40.3 | $0.1 | 0.2% |
| Subsidiaries | $30.7 | $29.6 | $1.1 | 3.7% |
| Distributors | $9.7 | $10.7 | ($1.0) | (9.7%) |
| Total | $116.5 | $107.7 | $8.8 | 8.2% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
